Phase I Trial of a Novel Anti-GD2 Monoclonal Antibody, Hu14.18K322A, Designed to Decrease Toxicity in Children With Refractory or Recurrent Neuroblastoma - Concepedia

Concepedia

Publication | Open Access

Phase I Trial of a Novel Anti-GD2 Monoclonal Antibody, Hu14.18K322A, Designed to Decrease Toxicity in Children With Refractory or Recurrent Neuroblastoma

DOI Full Paper Access

158

Citations

52

References

2014

Year

Fariba Navid, Paul M. Sondel, Raymond Barfield, Barry L. Shulkin, Robert A. Kaufman, Jim Allay, Jacek Gan, Paul R. Hutson, Songwon Seo, KyungMann Kim,

Journal of Clinical Oncology

Abstract

The MTD, and recommended phase II dose, of hu14.18K322A is 60 mg/m(2) per day for 4 days. Adverse effects, predominately pain, were manageable and improved with subsequent courses.

References

	Year	Citations

Page 1